World Asset Management Inc grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 49,126 shares of the biopharmaceutical company’s stock after purchasing an additional 636 shares during the quarter. World Asset Management Inc’s holdings in Gilead Sciences were worth $3,383,000 as of its most recent filing with the SEC.
A number of other institutional investors have also bought and sold shares of the business. Cascade Investment Advisors Inc. boosted its stake in Gilead Sciences by 0.6% in the second quarter. Cascade Investment Advisors Inc. now owns 25,300 shares of the biopharmaceutical company’s stock worth $1,742,000 after purchasing an additional 145 shares in the last quarter. Lehman & Derafelo Financial Resources LLC boosted its stake in Gilead Sciences by 0.6% in the second quarter. Lehman & Derafelo Financial Resources LLC now owns 24,330 shares of the biopharmaceutical company’s stock worth $1,675,000 after purchasing an additional 150 shares in the last quarter. Westhampton Capital LLC boosted its stake in Gilead Sciences by 3.5% in the second quarter. Westhampton Capital LLC now owns 4,410 shares of the biopharmaceutical company’s stock worth $304,000 after purchasing an additional 150 shares in the last quarter. Benjamin Edwards Inc. boosted its stake in Gilead Sciences by 1.0% in the first quarter. Benjamin Edwards Inc. now owns 15,337 shares of the biopharmaceutical company’s stock worth $991,000 after purchasing an additional 153 shares in the last quarter. Finally, Lyell Wealth Management LP boosted its stake in Gilead Sciences by 2.1% in the second quarter. Lyell Wealth Management LP now owns 7,604 shares of the biopharmaceutical company’s stock worth $524,000 after purchasing an additional 154 shares in the last quarter. 78.04% of the stock is currently owned by institutional investors.
In related news, CAO Diane E. Wilfong sold 13,610 shares of the stock in a transaction dated Tuesday, August 17th. The stock was sold at an average price of $72.50, for a total transaction of $986,725.00. Following the completion of the transaction, the chief accounting officer now directly owns 30,179 shares in the company, valued at $2,187,977.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.12% of the stock is currently owned by company insiders.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, July 29th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.76 by $0.11. The business had revenue of $6.22 billion during the quarter, compared to the consensus estimate of $6.15 billion. Gilead Sciences had a return on equity of 55.94% and a net margin of 19.38%. During the same period last year, the company earned $1.11 earnings per share. Equities analysts expect that Gilead Sciences, Inc. will post 7.15 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 29th. Investors of record on Wednesday, September 15th will be issued a dividend of $0.71 per share. The ex-dividend date of this dividend is Tuesday, September 14th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.97%. Gilead Sciences’s payout ratio is presently 40.06%.
Several equities analysts have recently issued reports on GILD shares. Royal Bank of Canada reaffirmed a “buy” rating and set a C$84.00 price target on shares of Gilead Sciences in a research note on Monday, August 23rd. Oppenheimer started coverage on Gilead Sciences in a research note on Monday, June 28th. They set a “buy” rating and a $100.00 price target on the stock. Morgan Stanley reaffirmed a “buy” rating and set a $83.00 price target on shares of Gilead Sciences in a research note on Friday, August 27th. BMO Capital Markets upped their price target on Gilead Sciences from $67.00 to $72.00 and gave the company a “market perform” rating in a research note on Friday, July 30th. Finally, SVB Leerink upped their price target on Gilead Sciences from $74.00 to $77.00 and gave the company an “outperform” rating in a research note on Friday, July 30th. Eight research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $104.74.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
See Also: Growth and Income Funds
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.